Effect of ascorbic acid in the treatment of tetanus.
The effect of daily intravenous administration of 1000 mg ascorbic acid (AA) in tetanus patients aged 1-30 years was studied. In the age group of 1-12 years, 31 patients were treated with AA as additional to antitetanus serum, sedatives and antibiotics. It was found that none of the patients died who received AA along with the conventional antitetanus therapy. On the other hand, 74.2 per cent of the tetanus patients who received the conventional antitetanus therapy without AA (control group) were succumbed to the infection. In the other age group of 13-30 years, there were 27 and 38 patients in the treatment and control groups respectively. The mortality in the AA and control groups were 37 percent and 67.8 percent respectively. These results suggest that AA might play an important role in reducing the mortality of tetanus. This was supported by the fact that AA was found to mitigate the toxic effects of strychnine producing tetanus like condition in young chicks in the present study.
D000293:Adolescent; D000328:Adult; D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D002645:Chickens; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D013331:Strychnine / Q000037:antagonists & inhibitors / Q000506:poisoning; D013742:Tetanus / Q000188:drug therapy*
D013331:Strychnine; D001205:Ascorbic Acid